Ripasudil hydrochloride dihydrate

개요Ripasudil hydrochloride hydrate (Glanatec®) was approved in Japan in 2014 for the treatment of glaucoma and ocular hypertension. Originally discovered by D. Western Therapeutics Institute, Inc. and licensed by the Kowa Company, Ltd, ripasudil functions as a selective Rho-kinase inhibitor and reduces intraocular pressure by stimulation of aqueous humour drainage of the trabecular meshwork. While this recent approval allows for use of ripasudil as a twice-daily monotherapy treatment when other drugs cannot be used or are not effective, clinical trials using ripasudil as a combination therapy with other glaucoma drugs have shown promising results in the treatment of primary open-angle glaucoma or ocular hypertension. Currently, the Kowa Company is also pursuing trials focused on the use of ripasudil for the treatment of diabetic retinopathy and diabetic macular edema.

용도Ripasudil Hydrochloride Dihydrate is a derivative of fasudil and a rho kinase inhibitor (1,2). It is used for the treatment of glaucoma and ocular hypertension.